Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas Mitsiades

Showing results (1-10 of 127) with videos related to

Pageof 13
Sort By:
Cancer Research|July 27, 2013
A road map to comprehensive androgen receptor axis targeting for castration-resistant prostate cancerNicholas Mitsiades
Endocrine-Related Cancer|June 15, 2021
Androgen receptor signaling inhibitors: post-chemotherapy, pre-chemotherapy and now in castration-sensitive prostate cancerNicholas Mitsiades, Salma Kaochar
Trends in Endocrinology and Metabolism: TEM|April 2, 2018
A Novel Mechanism to Drive Castration-Resistant Prostate CancerSalma Kaochar, Nicholas Mitsiades
Annual Review of Medicine|January 16, 2016
B-Raf Inhibition in the Clinic: Present and FutureWarren Fiskus, Nicholas Mitsiades
Hormones & Cancer|January 6, 2016
Moving Beyond the Androgen Receptor (AR): Targeting AR-Interacting Proteins to Treat Prostate CancerChristopher Foley, Nicholas Mitsiades
European Urology|December 28, 2020
Re: Umang Swami, Pedro Isaacsson Velho, Roberto Nussenzveig, et al. Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer. Eur Urol 2020;78:652-6: Can Mutant SPOP Become an Actionable Biomarker for Precision Oncology Management of Prostate Cancer?Salma Kaochar, Nicholas Mitsiades
Translational Cancer Research|July 31, 2019
Multimodal action of ONECUT2 in driving neuroendocrine prostate cancerSalma Kaochar, Nicholas Mitsiades
Expert Review of Anticancer Therapy|July 9, 2005
Treatment of hematologic malignancies and solid tumors by inhibiting IGF receptor signalingConstantine S Mitsiades, Nicholas Mitsiades
Oncotargets and Therapy|January 16, 2013
Clinical appraisal of abiraterone in the treatment of metastatic prostatic cancer: patient considerations, novel opportunities, and future directionsDiego J Bedoya, Nicholas Mitsiades
Thyroid : Official Journal of the American Thyroid Association|April 7, 2005
Thyroid carcinoma cells and Fas-mediated apoptosisConstantine S Mitsiades, Nicholas Mitsiades
Pageof 13

Showing results (1-10 of 127) with videos related to

Sort By:
Pageof 13
Cancer Research|July 27, 2013
A road map to comprehensive androgen receptor axis targeting for castration-resistant prostate cancerNicholas Mitsiades
Endocrine-Related Cancer|June 15, 2021
Androgen receptor signaling inhibitors: post-chemotherapy, pre-chemotherapy and now in castration-sensitive prostate cancerNicholas Mitsiades, Salma Kaochar
Trends in Endocrinology and Metabolism: TEM|April 2, 2018
A Novel Mechanism to Drive Castration-Resistant Prostate CancerSalma Kaochar, Nicholas Mitsiades
Annual Review of Medicine|January 16, 2016
B-Raf Inhibition in the Clinic: Present and FutureWarren Fiskus, Nicholas Mitsiades
Hormones & Cancer|January 6, 2016
Moving Beyond the Androgen Receptor (AR): Targeting AR-Interacting Proteins to Treat Prostate CancerChristopher Foley, Nicholas Mitsiades
European Urology|December 28, 2020
Re: Umang Swami, Pedro Isaacsson Velho, Roberto Nussenzveig, et al. Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer. Eur Urol 2020;78:652-6: Can Mutant SPOP Become an Actionable Biomarker for Precision Oncology Management of Prostate Cancer?Salma Kaochar, Nicholas Mitsiades
Translational Cancer Research|July 31, 2019
Multimodal action of ONECUT2 in driving neuroendocrine prostate cancerSalma Kaochar, Nicholas Mitsiades
Expert Review of Anticancer Therapy|July 9, 2005
Treatment of hematologic malignancies and solid tumors by inhibiting IGF receptor signalingConstantine S Mitsiades, Nicholas Mitsiades
Oncotargets and Therapy|January 16, 2013
Clinical appraisal of abiraterone in the treatment of metastatic prostatic cancer: patient considerations, novel opportunities, and future directionsDiego J Bedoya, Nicholas Mitsiades
Thyroid : Official Journal of the American Thyroid Association|April 7, 2005
Thyroid carcinoma cells and Fas-mediated apoptosisConstantine S Mitsiades, Nicholas Mitsiades
Pageof 13